Life Sciences Companies Adopt Veeva Nitro to Eliminate the Burden of Custom Data Warehouse Development and Maintenance
Veeva Systems (NYSE:VEEV) today announced that life sciences companies are adopting Veeva Nitro to accelerate their data warehouse projects and deliver faster insights to the business. Veeva Nitro is a life sciences-specific commercial data warehouse that eliminates the time and effort of custom data warehouses and provides a foundation for artificial intelligence (AI) and advanced analytics. In half a year since the product’s availability, six companies have selected Veeva Nitro, including Karyopharm Therapeutics (NASDAQ:KPTI) and MannKind Corporation (NASDAQ:MNKD), with both customers live and using the product in under five months.
With a fast-growing oncology business and a new therapy coming to market, Karyopharm Therapeutics needed to bring together a variety of data sets – including Veeva CRM and claims data – to empower field teams with the right information to reach the right stakeholders.
“Veeva Nitro removed many of the challenges in implementing a data warehouse and accelerated our ability to provide the field with useful, actionable insights,” said Jason Magyar, sr. director, enterprise applications, Karyopharm Therapeutics. “In just a few months, we gained a host of capabilities with Veeva Commercial Cloud and Veeva Nitro that other solutions sometimes take years to deliver, if ever. We now have a solid foundation for growth and to drive intelligent customer engagement.”
Veeva Nitro provides an industry-specific data model and standard integrations that unify a company’s most important data sources, including prescription, sales, formulary, and claims data. Data is automatically updated when data structures or sources change, eliminating the significant effort typically required to maintain a custom-built data warehouse.
Analytics-ready, Veeva Nitro also gives companies the flexibility to use the business intelligence and AI tools of their choice. With seamless integration to Veeva CRM MyInsights , any time data changes in Veeva Nitro it automatically syncs in Veeva CRM MyInsights. Now customers can deliver tailored insights to field teams right at the point of execution on any mobile device.
“Veeva Nitro allowed us to build and configure our data warehouse quickly and efficiently,” said Andrew Zepfel, associate director, sales operations, MannKind Corporation, a biopharmaceutical company that provides therapeutic products for patients with diseases such as diabetes. “Veeva Nitro will allow us to keep up with changes in the business as they happen and give us a foundation for advanced analytics.”
“For decades the life sciences industry has been held back by custom data warehouses that are inflexible and out-of-date, so they fail to deliver the right insights to the business,” said Andy Fuchs, vice president, Veeva Nitro. “Veeva Nitro finally gives companies a pre-built commercial data warehouse that is fast to deploy and delivers always current insights at speeds that were never before possible.”
Veeva Nitro is available today in North America and Japan and planned for availability in Europe in mid-2019.
To learn more about Veeva Nitro and how it can help build the foundation for intelligent engagement, watch this video from Matt Wallach, Veeva president.
For more on Veeva Nitro, visit: veeva.com/eu/Nitro
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva has more than 700 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. Veeva is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu .
This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions, particularly in the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended October 31, 2018. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov . Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.
® 2019 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
TX-PHYTON-BIOTECH18.4.2019 12:02:11 CEST | Pressemeddelelse
AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation
NY-BOIES-SCHILLER-FLEX18.4.2019 09:43:12 CEST | Pressemeddelelse
Racketeering Lawsuit Filed by Boies Schiller Flexner LLP Alleges Czech Oligarch Defrauds US Hedge Fund and Former Partner Out of Over $1 Billion
MITSUBISHI-HEAVY-IND18.4.2019 09:23:11 CEST | Pressemeddelelse
MHI Thermal Systems Develops Demonstration Unit of the World’s First Small-Capacity Residential Air-Conditioner Adopting the Low-GWP R454C Refrigerant
MA-HOLOGIC-INC18.4.2019 09:02:09 CEST | Pressemeddelelse
Hologic Receives European CE Mark for ThinPrep® Genesis Processor, an Automated Cytology Slide and Molecular Sample System
SARTORIUS18.4.2019 07:02:15 CEST | Pressemeddelelse
Sartorius Starts off Fiscal 2019 with a Strong First Quarter
IPSEN/CLEMENTIA18.4.2019 07:02:05 CEST | Pressemeddelelse
Ipsen Completes Acquisition of Clementia Pharmaceuticals
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.Besøg vores nyhedsrum